Ganitumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Ganitumab
Accession Number
DB12205
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Ganitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
CK1441RCZ8
CAS number
905703-97-1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Ganitumab.
AbituzumabThe risk or severity of adverse effects can be increased when Ganitumab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Ganitumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Ganitumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Ganitumab.
AducanumabThe risk or severity of adverse effects can be increased when Ganitumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Ganitumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ganitumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Ganitumab.
AmatuximabThe risk or severity of adverse effects can be increased when Ganitumab is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Evidence Level

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911298
Wikipedia
Ganitumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentMalignant Lymphomas / Prostate Cancer / Sarcomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentNeoplasm Metastases1
1, 2CompletedTreatmentColorectal Cancers / Gastrointestinal Cancers / Malignant Neoplasm of Colon / Metastatic Colorectal Cancers / Rectal Carcinoma1
1, 2RecruitingTreatmentRhabdomyosarcoma- Alveolar / Rhabdomyosarcoma-Embryonal / Rhabdomyosarcomas1
1, 2TerminatedTreatmentPIK3CA Amplified Advanced Solid Tumors / PIK3CA Mutated Advanced Solid Tumors1
1, 2WithdrawnTreatmentMalignant Neoplasm of Pancreas1
2Active Not RecruitingTreatmentAdvanced Solid Tumors / Carcinoids / Colorectal Cancers / Locally Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Lymphomas / Metastatic Cancers / Sarcomas / Tumors, Solid1
2CompletedTreatmentCarcinoid Tumors / Neuroendocrine Tumors / Progressive Neuroendocrine Tumors of pancreatic origin1
2CompletedTreatmentMetastatic Colorectal Cancers1
2RecruitingTreatmentCancer, Breast / Neoplasms, Breast / Tumors, Breast1
2TerminatedTreatmentBRAF Mutated Melanoma / KRAS Mutated Colorectal Adenocarcinoma / Pancreatic Adenocarcinoma Metastatic1
3Active Not RecruitingTreatmentMetastatic Ewing Sarcoma / Metastatic Malignant Neoplasm in the Bone / Metastatic Malignant Neoplasm in the Bone Marrow / Metastatic Malignant Neoplasm in the Lung / Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone / Peripheral Primitive Neuroectodermal Tumor of Soft Tissues1
Not AvailableNo Longer AvailableNot AvailableEwing's Sarcoma (ES)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 15:36 / Updated on May 01, 2019 11:24